The health and wellbeing of any workforce is a core priority and taking steps to ensure the wellbeing of employees is an important part of everyday working life. Winter is a time of particular challenge and is linked to increased absenteeism. There is a growing awareness that probiotics (similar to the bacteria found in yogurts) can play a role in boosting general wellbeing. Probiotics are known as 'good' or 'friendly' bacteria and are living organisms that are found naturally in yogurt and fermented foods. They can be capsules, tablets or powders in sachets that are taken daily to help to keep the gut in peak condition. Everyone has trillions of bacteria in their guts living together happily and they are needed to boost our wellbeing but the stresses and strains of everyday life can often disturb their balance, probiotics can help to restore the balance. Over the winter of 2022, a small exploratory study with employees based in South Wales who were offered the opportunity to 'try out' a probiotic manufactured by Cultech Limited (a company based in Port Talbot specialising in the production of nutritional supplements). The results were very promising with significant improvements in wellbeing and reduced absenteeism among those who opted to take the product. This project is designed as a follow-up on last year's exploratory study by including a placebo version alongside the probiotic and introduce a randomisation process to assess the effectiveness of the same probiotic nutritional supplement over the winter

开始日期2023-10-02

申办/合作机构

Cultech Ltd.

NCT05355571 / CompletedN/A

The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function And/or Faecal Microbiota Composition (FANTIB)

To investigate whether probiotic supplementation during the consumption of oral antibiotics can impact gastrointestinal responses and/or the regrowth of the gut microbiota.

开始日期2022-11-18

申办/合作机构

Cultech Ltd.

[+1]

100 项与 Cultech Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Cultech Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Cultech Ltd. 相关的文献（医药）

2024-04-01·Neurogastroenterology & Motility

A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females

Article

作者: Plummer, S F ; Webberley, T S ; Michael, D R ; Wang, D ; Marchesi, J R ; Luo, Y ; Coates, N ; Dabcheva, M ; Mullish, B H ; John, D A

AbstractBackgroundA previous exploratory study demonstrated the ability of the Lab4 probiotic to alleviate the symptoms of IBS, and post hoc data analysis indicated greatest improvements in the female subgroup. The aim of this study is to confirm the impact of this multistrain probiotic on IBS symptom severity in females.MethodsAn 8‐week, single‐center, randomized, double‐blinded, placebo‐controlled, superiority study in 70 females with Rome IV‐diagnosed irritable bowel syndrome (IBS) receiving the Lab4 probiotic (25 billion colony‐forming units) daily or a matched placebo. Changes from baseline in the IBS‐symptom severity score (IBS‐SSS), daily bowel habits, anxiety, depression, IBS‐related control, and avoidance behavior, executive function, and the fecal microbiota composition were assessed. The study was prospectively registered: ISRCTN 14866272 (registration date 20/07/22).Key ResultsAt the end of the study, there were significant between‐group reductions in IBS‐SSS (−85.0, p < 0.0001), anxiety and depression scores (−1.9, p = 0.0002 and −2.4, p < 0.0001, respectively), and the IBS‐related control and avoidance behavior score (−7.5, p = 0.0002), all favoring the probiotic group. A higher proportion of the participants in the probiotic group had normal stool form (p = 0.0106) and/or fewer defecations with loose stool form (p = 0.0311). There was little impact on the overall diversity of the fecal microbiota but there were significant differences in Roseburia, Holdemanella, Blautia, Agathobacter, Ruminococcus, Prevotella, Bacteroides, and Anaerostipes between the probiotic and placebo groups at the end of the study.Conclusions & InferencesDaily supplementation with this probiotic may represent an option to be considered in the management of IBS.

2023-05-01·Journal of Functional Foods

Does flow culture impact upon gut-probiotic interactions: A comparison with static culture

作者: Webberley, T. S. ; Plummer, S. F. ; Marchesi, J. R. ; Parry, L. ; Murphy, K. R. ; Michael, D. R. ; Kerry-Smith, J.

Conventional tissue culture models often lack physiol. relevance.In this exploratory study, dynamic flow conditions were applied to 21-day cultured Caco-2 intestinal epithelial cells and their response compared with statically cultured counterparts.Host: microbiome interactions were also explored through co-incubation with Gram pos. bacteria (Lab4 probiotics) or the Gram pos. cell wall component, lipoteichoic acid (LTA).Under flow, Caco-2 cells displayed increased viability, mucin production and pH tolerance compared to cells under static conditions.Measurement of secretion rates of the pro-inflammatory cytokine, interleukin-8, showed that cells under flow were unresponsive towards stimulation with Lab4 or LTA that was in complete contrast to inductions observed under static conditions.Given that Gram pos. bacteria are well tolerated within the healthy gastrointestinal tract, these data suggest that flow conditions may improve the physiol. relevance of Caco-2 cells.This preliminary study encourages further work exploring the impact of flow on cell-based in vitro models.

2023-01-01·Beneficial Microbes

The gastrointestinal status of healthy adults: a post hoc assessment of the impact of three distinct probiotics

Article

作者: Marchesi, J.R. ; John, D. ; Wang, D. ; Michael, D.R. ; Mullish, B.H. ; Webberley, T.S. ; Ramanathan, G. ; Plummer, S.F.

There is a growing awareness that supplementation with probiotic bacteria can impart beneficial effects during gastrointestinal disease, but less is known about the impact of probiotics on healthy subjects. Here, we report the outcomes of a post hoc analysis of recorded daily gastrointestinal events and bowel habits completed by healthy adults participating in a placebo-controlled, single-centre, randomised, double-blind, quadruple-arm probiotic tolerability study. Extensive screening ensured the healthy status of subjects entering the study and during a 2-week pre-intervention run-in period, a burden of gastrointestinal events (stomach pains, indigestion, acid reflux, stomach tightening, nausea and vomiting, stomach rumbling, bloating, belching and flatulence) was identified suggesting GI discomfort within the population. In the subsequent 12-week intervention period with 3 distinct probiotic formulations and a matched-placebo, reductions in the incidence rates of bloating, borborygmus, stomach pains, slow faecal transit and incomplete defecations were observed in the probiotic groups compared to the placebo. These results highlighted differing responses among the probiotic formulations tested and indicated potential anti-constipation effects. Product specific modulations in circulating interleukin-6 levels and in the composition of the gut microbiota were also detected. Together, these data suggest a role for probiotic supplementation to exert beneficial effects on the gastrointestinal functioning of healthy subjects and highlight the need for further longer-term studies in healthy populations to gain a greater understanding of the impact of probiotics.

100 项与 Cultech Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Cultech Ltd. 相关的转化医学

登录后查看更多信息